OCU400
OCU400
COVAXIN
STUDY OVERVIEW
The Phase 1/2 clinical study to evaluate the safety and efficacy of OCU400 for Retinitis Pigmentosa associated with NR2E3 and RHO mutations, utilizing unilateral sub-retinal injection (one eye per study subject) in up to 18 patients, with an extension for contralateral eye and long-term safety follow up.
CURRENTLY RECRUITING
Yes
FOR MORE INFORMATION
QUESTIONS?
Contact us at
STUDY TITLE
A Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa associated with NR2E3 and RHO mutations
MEDICAL CONDITION(S)
Retinal degeneration resulting from genetic mutations NR2E3, RHO
PRODUCT
AAV-NR2E3
Received orphan drug designation
OCUGEN PROTOCOL NUMBER
OCU400-101
NUMBER OF SUBJECTS
Up to 18 adults who meet eligibility criteria
STUDY LENGTH
12 months
SEX
Male & Female
STUDY DATES
January 2022 – April 2023
AGE
18+
PHASE
1/2
COUNTRY
United States
STAY CONNECTED
Contact us for more information
Copyright @ 2021.